Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Prepaid Assets (2018 - 2025)

Historic Prepaid Assets for Abvc Biopharma (ABVC) over the last 13 years, with Q3 2025 value amounting to $447280.0.

  • Abvc Biopharma's Prepaid Assets rose 29148.89% to $447280.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $447280.0, marking a year-over-year increase of 29148.89%. This contributed to the annual value of $96213.0 for FY2024, which is 478.77% down from last year.
  • Abvc Biopharma's Prepaid Assets amounted to $447280.0 in Q3 2025, which was up 29148.89% from $194999.0 recorded in Q2 2025.
  • In the past 5 years, Abvc Biopharma's Prepaid Assets registered a high of $1.3 million during Q2 2022, and its lowest value of $96213.0 during Q4 2024.
  • In the last 5 years, Abvc Biopharma's Prepaid Assets had a median value of $287181.0 in 2022 and averaged $392430.4.
  • Per our database at Business Quant, Abvc Biopharma's Prepaid Assets soared by 89288.5% in 2021 and then crashed by 8862.62% in 2023.
  • Abvc Biopharma's Prepaid Assets (Quarter) stood at $528354.0 in 2021, then tumbled by 71.57% to $150235.0 in 2022, then plummeted by 32.74% to $101051.0 in 2023, then dropped by 4.79% to $96213.0 in 2024, then surged by 364.89% to $447280.0 in 2025.
  • Its Prepaid Assets was $447280.0 in Q3 2025, compared to $194999.0 in Q2 2025 and $96362.0 in Q1 2025.